This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.89% per year. These returns cover a period from January 1, 1988 through March 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ETFs to Tap China's Economic Resurgence in 2024
by Yashwardhan Jain
With promising economic data and optimistic growth projections, the Chinese economy stands poised for a potential resurgence in 2024. Explore ETFs to leverage and capitalize on China's anticipated economic revival.
Time to Buy These China ETFs on Surprise Monetary Easing?
by Sanghamitra Saha
China's central bank surprised the market by announcing its second key policy rate cut in three months on Aug 17, 2023.
Country Garden Crisis Puts China ETFs in the Spotlight
by Yashwardhan Jain
Amidst China's ongoing real estate turmoil, the challenges faced by Country Garden hinder the sector's recovery efforts. Explore ETFs to navigate this uncertain terrain in the world's second-largest economy
Top-Performing ETF Areas of Last Week
by Sanghamitra Saha
Wall Street recorded a moderate performance last week. But the final week of the year was not that bad. This was probably because of the muted Santa Clause rally.
China ETFs Rallying: Top Gainers Past Month
by Sanghamitra Saha
China ETFs have been rallying of late to reflect easing Covid controls and a sweeping rescue package to bail out developers.
5 Top-Performing ETFs of Last Week
by Sanghamitra Saha
Wall Street was downbeat last week on inflationary concerns and some downbeat economic data points.
Best-Performing ETF Areas of Last Week
by Sanghamitra Saha
Last week was slightly downbeat for Wall Street on talks of a capital gain tax hike with three big U.S. indexes remaining in the red.
Top ETF Areas of Last Week
by Sanghamitra Saha
The markets rallied because Biden started his term by signing a number of executive orders to counter the ill effects of the COVID-19 pandemic, empower environmental protection initiatives and roll back many of the Trump administration's immigration policies.
5 Reasons to Bet on China ETFs
by Sanghamitra Saha
The Chinese economy returned to growth in the second quarter of 2020. This along with PBOC's targeted policy easing and China's solid tech industry make China investing winners in the recent trading sessions.
6 China ETFs From 3 Sectors That Emerged Winners in June
by Sanghamitra Saha
A host of China ETFs outperformed in June. These funds come mainly from the technology, healthcare and clean energy segments.
3 Best Country ETFs of 1H That Survived the Pandemic
by Sweta Killa
While most the countries' stocks have been beaten down badly in the pandemic, some still managed to trade in green for the first half of the year.
China Healthcare ETF (KURE) Hits New 52-Week High
by Sanghamitra Saha
The fund hit a 52-week high lately. Can this go further higher?
6 Equity ETFs in Green Last Week Despite Wall Street Bloodbath
by Sanghamitra Saha
Overall, the S&P 500, the Dow Jones, the Nasdaq Composite and the Russell 2000 added 4.8%, 5.6%, 1.6%, and 7.9% last week, respectively.
China Healthcare ETF (KURE) Hits New 52-Week High
by Sanghamitra Saha
The fund KURE hit a 52-week high on May 14. Can it sustain the rally?
These China ETFs Hardly Felt Any Coronavirus Pain in Q1
by Sanghamitra Saha
Despite being the epicenter of the coronavirus, China ETFs held up pretty well in the first quarter.
5 International Equity ETFs That Topped S&P 500 in Q1
by Sanghamitra Saha
These international ETFs have outperformed the S&P 500 in the first quarter.
Wall Street in Correction: 4 Sector ETFs Unscathed in February
by Sanghamitra Saha
These sector ETFs gained or lost the least in the coronavirus-induced rout in February.
What Lies in China ETFs' Fortunes in the Year of Rat?
by Sanghamitra Saha
China ETFs delivered decent performance in the year of the pig. What would the year of the rat bring?
Don't Fear China's Weaker Growth, Play It With These ETFs
by Sanghamitra Saha
Many investors may be worrying about slowing growth of the Chinese economy. But government efforts and trade optimism bode well for ETFs.
Stimulus Hopes Boost China's Stocks: ETFs Gain the Most
by Sanghamitra Saha
China's stocks surge maximum in more than two years on hopes of authorities' support. Is it time to buy these ETFs?
Top and FLOP ETFs of Last Week
by Sanghamitra Saha
Inside the top and worst-performing ETFs of last week.
Explore China's Booming Biopharma Space With This New ETF
by Sanghamitra Saha
Inside the new China bio-pharma ETF and its possibilities.